Animation prostate – Medical Animation Prostate Cancer

Scientists For The First Time Identify Cell-Of-Origin For Human Prostate Cancer
UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease...

New Surgery Without Incisions Shows Promise For Prostate Cancer Treatment
With a recent first of its kind surgery, physicians at Mayo Clinic in Arizona have developed a new surgical procedure for the treatment of prostate cancer using natural orifices - signaling the next step in the evolution of minimally invasive surgery. Removing the prostate is a common treatment for patients with prostate cancer, which affects one in six men in the U.S...

New England Journal Of Medicine Publishes Data From Pivotal Phase 3 PROVENGE IMPACT Study
Dendreon Corporation (Nasdaq: DNDN) announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC)...

Dense Bones Linked To Raised Risk For Prostate Cancer
Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health...

NYU Langone Begins Clinical Trial Offering Vascular-Targeted Photodynamic Therapy To Patients With Localized Prostate Cancer
NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells...

Don't Blame The PSA Test For The 'Overtreatment' Of Prostate Cancer
A new report published in the July 26 issue of Archives of Internal Medicine claims many men who are diagnosed with prostate cancer undergo aggressive therapy, even when they have low PSA scores and low-risk disease, saying "these results underscore the fact that PSA level, the current biomarker, is not a sufficient basis for treatment decisions...

AMD Appoints BK Medical As Agent For Prostate HistoScanningâ„¢ In The UK
Advanced Medical Diagnostics SA (AMD), a privately held company committed to providing innovative computer-aided solutions (HistoScanningâ„¢) that can improve the diagnostic interpretation of ultrasound scans, announced that it has appointed BK Medical UK Ltd as sole agent for Prostate HistoScanningâ„¢ in the UK...

Proposed Lowering Of PSA Threshold For Biopsy Could Result In Increased Overdiagnosis And Overtreatment Of Prostate Cancer, Study
New research from the US suggests that most American men diagnosed with prostate cancer receive aggressive treatment, even if their prostate-specific antigen (PSA) level is below the current recommended 4...

Profile: Most Low-Risk Prostate Cancer Patients Receive Aggressive Treatment
Controversy has long existed over the benefit of the prostate specific antigen (PSA) test used to screen for the presence of prostate cancer, and there has been little study to document the risk profile of men who have a PSA level at or below what is considered 'normal.' New research published in the latest edition of Archives of Internal Medicine (Vol. 170, No...

Samuel Oschin Comprehensive Cancer Institute Has New GPS-Like System That Delivers More Focused Radiation To Prostate Cancer Tumors
A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute...

Association Of Body Mass Index With Prostate Cancer Biochemical Failure
UroToday.com - Our study of prostate cancer patients' outcomes relative to their body mass index (BMI) is interesting because of the lack of effect we observed between BMI and the study's endpoint: biochemical failure...

[-2]Proenzyme Prostate Specific Antigen Is More Accurate Than Total And Free Prostate Specific Antigen In Differentiating
UroToday.com - Prostate Specific Antigen (PSA), the primary means of diagnosing prostate cancer in the modern era, lacks specificity in differentiating benign from malignant disease. Thus clinical decisions based on PSA may lead to unnecessary biopsies in some while overlooking biopsies in others...

The Launch And Uptake Of Nine Emerging Therapies Will Drive The Prostate Cancer Drug Market To More Than Double To $8.4 Billion In 2019
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of nine emerging therapies will drive the prostate cancer drug market to more than double from nearly $4 billion in 2009 to $8.4 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan...

Researchers Block Pathway That Performs Key Function In End-Stage Prostate Cancer
Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth...

CytRx Announces Substantial Progress With Its Bafetinib Clinical Trials Program
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications...